Oversubscribed Series B to take Protego’s AL amyloidosis program into pivotal study

San Diego-based Protego Biopharma, a biotech developing small molecule therapeutics that reprogram protein folding to address systemic amyloid diseases and other protein misfolding disorders, has completed an oversubscribed $130 million Series B financing.

Proceeds will advance Protego’s lead candidate, PROT-001, into a pivotal clinical trial for AL amyloidosis, a rare and often fatal condition caused by protein misfolding that leads to organ damage, especially in the heart.

The round was led by Novartis Venture Fund and Forbion, with participation from new investors including Omega Funds, Droia Ventures, YK Bioventures, and Digitalis Ventures.